手法を比較

	小児用DLQI (cDLQI)	SCORAD指数（アトピー性皮膚炎スコアリング）	Skindex-29（皮膚疾患QOL評価尺度）
分野	皮膚科学	皮膚科学	皮膚科学
系統	Process / pipeline	Process / pipeline	Process / pipeline
提唱年	1995	1993	1997
提唱者	Lewis-Jones MS, Finlay AY	European Task Force on Atopic Dermatitis (ETFAD)	Chren MM, Lasek RJ
種類	Self-report (parent or child proxy)	Clinician-rated	Self-report
原典	Lewis-Jones MS, Finlay AY. The Children's Dermatology Life Quality Index (cDLQI): initial validation and practical use. Br J Dermatol. 1995;132(6):942-949.	Kunz B, Oranje AP, Labrèze L, et al. Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. Dermatology. 1997;195(1):10-19.	Chren MM, Lasek RJ, Quinn LM, et al. Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness. J Invest Dermatol. 1997;107(5):707-713.
別名	cDLQI, Pediatric DLQI	SCORAD Index	Skindex, Skindex-QoL
関連	3	3	1
概要	The Children's Dermatology Life Quality Index (cDLQI) is a pediatric-adapted version of the adult DLQI, measuring the impact of skin disease on quality of life in children and adolescents aged 4–16 years. Developed by Lewis-Jones and Finlay in 1995, it uses child-friendly language and addresses domains relevant to childhood (school, leisure, friendships, clothing) rather than work and adult relationships. cDLQI is the standard quality-of-life measure in pediatric dermatology trials and clinical practice.	The SCORAD is a comprehensive clinician-administered tool for measuring the extent and severity of atopic dermatitis (eczema). Developed by the European Task Force on Atopic Dermatitis in 1993, it combines objective clinical assessment with subjective symptom reporting. It is the gold standard for atopic dermatitis severity in clinical trials and dermatology practice.	Skindex-29 is a validated, patient-centered quality-of-life measure specifically designed to assess the impact of any skin disease on patients' symptoms, emotions, and functioning. Developed by Chren, Lasek, and colleagues in 1997, it captures the multidimensional burden of dermatological conditions beyond clinical severity. Skindex-29 is widely used in clinical trials, observational studies, and dermatology practice to ensure that treatment efficacy encompasses quality-of-life outcomes.